<DOC>
	<DOCNO>NCT02107885</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled ascend single dose study . It hypothesise single oral dos DS-1971a within plan dose range safe well tolerate healthy male subject .</brief_summary>
	<brief_title>Single Ascending Dose Study Using DS-1971 Assess Safety , Tolerability , Pharmacokinetics Healthy Participants .</brief_title>
	<detailed_description />
	<criteria>Healthy male subject age 1845 year . A body mass index ( BMI Quetlet index ) range 1830 kg/m^2 , inclusive , weigh 50 100 kg screening . Body Mass Index ( BMI ) =weight [ kg ] / ( height [ ] ) ^2 Willing use reliable method contraception donate sperm study , 4 month afterwards . Sufficient intelligence understand nature study hazard participate . Ability communicate satisfactorily Investigator participate , comply requirement , entire study . Willing give write consent participate study read ICF , opportunity discus study Investigator delegate . Willing give write consent data enter The Overvolunteering Prevention System . Clinically relevant abnormal history , physical finding , ECG finding , laboratory value could interfere objective study compromise safety subject . Presence history acute chronic illness , include ( limited ) liver kidney disease , hypertension , seizure , know impairment endocrine , specific bodyorgan dysfunction . History serious reaction medicine . Presence history malignant disease . Acute chronic infectious disease , include HIV , HBV HCV infection . Surgery ( e.g . stomach bypass ) medical condition might affect body handle absorb medicine . Significant illness within 4 week dose trial medication . Participation another clinical trial new chemical entity prescription medicine within previous 3 month , unwilling abstain participate clinical trial study 3 month receipt trial medication . Abnormal ECG waveform morphology screen would preclude accurate measurement QT interval duration . QTcF interval duration &gt; 430 msec , obtain average 3 ECG measurement triplicate screen ECGs . Estimated glomerular filtration rate ( eGFR ) &lt; 90 mL/min/1.73m^2MDRD ] equation ) . Use prescription OTC medication know strong inhibitor strong inducer CYP enzyme ( also know CYP P450 enzymes ) 30 day dose trial medication ; use prescription OTC medicine include vitamin herbal remedy like St John 's wort , exception acetaminophen ( paracetamol ) , 7 day dose trial medication . Consumption grapefruit , grapefruit juice Seville oranges within 10 day dose trial medication , unwilling abstain consume throughout study . Consumption food beverage contain caffeine xanthine within 24 h admission Day 1 , unwilling abstain consume 3 day receive trial medication . Loss 400 mL blood 3 month study . Donation blood , plasma , platelet , blood component 3 month study , unwilling abstain study 3 month receipt trial medication . Abuse drug alcohol 2 year dose trial medication , intake 21 unit alcohol weekly . Use tobacco product nicotinecontaining product 3 month dose trial medication . Evidence drug alcohol abuse screen admission . Likely possibility volunteer cooperate requirement protocol . Objection GP volunteer enter study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>